Stemline Therapeutics Inc (STML)

9.10
NASDAQ : Health Care
Prev Close 8.50
Day Low/High 8.05 / 9.65
52 Wk Low/High 5.50 / 14.60
Avg Volume 178.00K
Exchange NASDAQ
Shares Outstanding 25.12M
Market Cap 213.48M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Stemline Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Stemline Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed A Complaint To Recover Losses Suffered By Investors In Stemline Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc.

STML SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Stemline Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 4, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Stemline Therapeutics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

STML LOSS NOTICE: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors Of Important Deadline In First Class Action Filed By Firm - STML

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Stemline Therapeutics, Inc.

Short Interest In Stemline Therapeutics Drops 44.6%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 599,096 share decrease in total short interest for Stemline Therapeutics Inc , to 744,915, a decrease of 44.58% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.